Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313383817> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4313383817 endingPage "54.3" @default.
- W4313383817 startingPage "54.3" @default.
- W4313383817 abstract "Abstract Farnesol is a 15-carbon organic acyclic sesquiterpene alcohol (isoprenol) produced by plants and animals. It is a potent blocker of neuronal voltage-gated Ca2+ found in the human brain. It has potent anti-oxidant and antiinflammatory effects in vitro, and neuroprotection based on the regulation of free radicals production by glial cells was demonstrated in a murine model of neurotoxicity. Because inflammation, oxidative stress and intraneuronal Ca2+ overload are associated with central nervous system (CNS) demyelinating diseases, we sought to determine if farnesol treatment would result in protection against experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS). We compared the progression of EAE in C57BL/6 mice treated orally with farnesol (100 mg/kg/daily by gavage in olive oil) versus EAE progression in untreated mice (control) (n = 10/group). Treatment started at EAE induction and continued for 25 days. EAE clinical severity was monitored daily. Factorial repeated measures ANOVA of the scores showed: 1) a significant Day effect (disease onset 9 days after induction), 2) a significant Group effect (approx. 80% reduction in scores in the Farnesol group), and 3) a significant Day * Group interaction with scores being significantly lower in the Farnesol group every day starting one day after disease onset. At day 25, 50% of control mice had been euthanized due to scores ≥ 3.5 vs. none in the Farnesol group. Our results indicate that Farnesol significantly reduces disease onset in EAE. Studies to elucidate the mechanism of action of farnesol, screening of structural analogues of farnesol for anti-EAE activity, and assessment of farnesol therapeutic efficacy in other animal models of MS are being conducted." @default.
- W4313383817 created "2023-01-06" @default.
- W4313383817 creator A5010775138 @default.
- W4313383817 creator A5027157574 @default.
- W4313383817 creator A5032501205 @default.
- W4313383817 creator A5035950996 @default.
- W4313383817 creator A5043004575 @default.
- W4313383817 creator A5053174813 @default.
- W4313383817 creator A5068781531 @default.
- W4313383817 date "2018-05-01" @default.
- W4313383817 modified "2023-09-29" @default.
- W4313383817 title "Isoprenol-Induced Neuroprotection in Experimental Multiple Sclerosis" @default.
- W4313383817 doi "https://doi.org/10.4049/jimmunol.200.supp.54.3" @default.
- W4313383817 hasPublicationYear "2018" @default.
- W4313383817 type Work @default.
- W4313383817 citedByCount "1" @default.
- W4313383817 countsByYear W43133838172023 @default.
- W4313383817 crossrefType "journal-article" @default.
- W4313383817 hasAuthorship W4313383817A5010775138 @default.
- W4313383817 hasAuthorship W4313383817A5027157574 @default.
- W4313383817 hasAuthorship W4313383817A5032501205 @default.
- W4313383817 hasAuthorship W4313383817A5035950996 @default.
- W4313383817 hasAuthorship W4313383817A5043004575 @default.
- W4313383817 hasAuthorship W4313383817A5053174813 @default.
- W4313383817 hasAuthorship W4313383817A5068781531 @default.
- W4313383817 hasConcept C126322002 @default.
- W4313383817 hasConcept C185592680 @default.
- W4313383817 hasConcept C203014093 @default.
- W4313383817 hasConcept C25498285 @default.
- W4313383817 hasConcept C2776151105 @default.
- W4313383817 hasConcept C2776914184 @default.
- W4313383817 hasConcept C2778486448 @default.
- W4313383817 hasConcept C2779247237 @default.
- W4313383817 hasConcept C2779491297 @default.
- W4313383817 hasConcept C2780640218 @default.
- W4313383817 hasConcept C29730261 @default.
- W4313383817 hasConcept C529278444 @default.
- W4313383817 hasConcept C55493867 @default.
- W4313383817 hasConcept C71924100 @default.
- W4313383817 hasConcept C98274493 @default.
- W4313383817 hasConceptScore W4313383817C126322002 @default.
- W4313383817 hasConceptScore W4313383817C185592680 @default.
- W4313383817 hasConceptScore W4313383817C203014093 @default.
- W4313383817 hasConceptScore W4313383817C25498285 @default.
- W4313383817 hasConceptScore W4313383817C2776151105 @default.
- W4313383817 hasConceptScore W4313383817C2776914184 @default.
- W4313383817 hasConceptScore W4313383817C2778486448 @default.
- W4313383817 hasConceptScore W4313383817C2779247237 @default.
- W4313383817 hasConceptScore W4313383817C2779491297 @default.
- W4313383817 hasConceptScore W4313383817C2780640218 @default.
- W4313383817 hasConceptScore W4313383817C29730261 @default.
- W4313383817 hasConceptScore W4313383817C529278444 @default.
- W4313383817 hasConceptScore W4313383817C55493867 @default.
- W4313383817 hasConceptScore W4313383817C71924100 @default.
- W4313383817 hasConceptScore W4313383817C98274493 @default.
- W4313383817 hasIssue "1_Supplement" @default.
- W4313383817 hasLocation W43133838171 @default.
- W4313383817 hasOpenAccess W4313383817 @default.
- W4313383817 hasPrimaryLocation W43133838171 @default.
- W4313383817 hasRelatedWork W2061140793 @default.
- W4313383817 hasRelatedWork W2082194413 @default.
- W4313383817 hasRelatedWork W2143377477 @default.
- W4313383817 hasRelatedWork W2173908654 @default.
- W4313383817 hasRelatedWork W2482532620 @default.
- W4313383817 hasRelatedWork W2582648722 @default.
- W4313383817 hasRelatedWork W2783447283 @default.
- W4313383817 hasRelatedWork W4297019876 @default.
- W4313383817 hasRelatedWork W4319433888 @default.
- W4313383817 hasRelatedWork W60425281 @default.
- W4313383817 hasVolume "200" @default.
- W4313383817 isParatext "false" @default.
- W4313383817 isRetracted "false" @default.
- W4313383817 workType "article" @default.